Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil [Phase 3]
An extension Phase 3 study is evaluating the long-term safety of dry powder inhaled treprostinil (LIQ861) in patients with pulmonary arteria…
-
FDA approval · 2025-01-23FDA Approved: BOSENTAN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Bosentan from Actavis Pharma, authorizing a generic version under ANDA207110.
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease
This completed clinical trial assessed the prevalence and clinical manifestations of SARS-CoV-2 infection in adult and pediatric patients wi…
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
A clinical trial update examining real-world use of next-generation infusion pumps to administer Remodulin for pulmonary arterial hypertensi…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)
A completed clinical trial at UT Southwestern Medical Center investigating metabolic remodeling in pulmonary arterial hypertension. The stud…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-01-03Clinical Trial Update: TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
The clinical trial 'Transpulmonary Estrogen Gradient and Estrogen Receptors (TYEGER)' for pulmonary arterial hypertension has been withdrawn…
-
CLINICAL_TRIALS research · 2024-12-31Clinical Trial Update: Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
A multicenter real-world trial evaluating the efficacy and safety of triple-targeted therapy in treatment-naive patients with non-low-risk p…
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension
This entry reports a recruiting clinical trial evaluating exercise capacity, muscle oxygenation, and arterial stiffness in children with pul…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects [Phase 1]
A Phase 1 pharmacokinetic and safety study of TPN171H tablets in patients with renal insufficiency and healthy subjects has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 clinical trial evaluating the acute hemodynamic effects of TPN171H in patients with pulmonary arterial hypertension has completed.
-
FDA approval · 2024-12-16FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA has approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC.
-
FDA approval · 2024-12-16FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Pfizer Laboratories, indicating an update/expansio…
-
FDA approval · 2024-12-12FDA Approved: OPSYNVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA supplemental application for OPSYNVI (macitentan and tadalafil) by Actelion Pharmaceuticals US, Inc. seeks regulatory action on NDA21849…
-
FDA approval · 2024-12-12FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) by Actelion Pharmaceuticals US, Inc., regarding an updated/expanded app…
-
FDA approval · 2024-12-12FDA Approved: SILDENAFIL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for sildenafil, resulting in approval of a generic sildenafil product.
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 clinical trial evaluating tamoxifen therapy for pulmonary arterial hypertension has completed, with results posted in December 202…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx [Phase 4]
Phase 4 clinical trial recruiting to evaluate intensification and personalisation of combination therapy for Pulmonary Arterial Hypertension…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension [Phase 1]
Phase 1/1b study of nab-sirolimus for severe pulmonary arterial hypertension has completed, with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study [Phase 3]
Phase 3 clinical trial update reporting results for selexipag in participants who previously took part in a prior selexipag study; results h…
-
CLINICAL_TRIALS research · 2024-11-14Clinical Trial Update: Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
This feasibility study evaluates non-invasive pulmonary arterial pressure monitoring in ICU patients using electrical impedance tomography a…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: The CardioMEMS Vericiguat Heart Failure Trial [Phase 4]
Phase 4 clinical trial update for the CardioMEMS-Vericiguat Heart Failure study; the trial is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso [Phase 1]
An open-label Phase 1 study evaluated the safety and tolerability of TreT in patients with pulmonary arterial hypertension who are currently…
-
EMA approval · 2024-10-25EMA Authorised: Tracleer (bosentan (as monohydrate)) — Janssen-Cilag International N.V.
The European Medicines Agency authorised Tracleer (bosentan) for systemic sclerosis and for pulmonary arterial hypertension.
-
FDA label_change · 2024-10-25FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC, resulting in changes to the pro…
-
EMA approval · 2024-10-24EMA Authorised: Stayveer (bosentan (as monohydrate)) — Janssen-Cilag International NV
The EMA authorised Stayveer (bosentan) for use in pulmonary arterial hypertension and systemic sclerosis (scleroderma) in the European Union…